These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18060082)

  • 1. Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.
    Lecoeur H; Buffet P; Morizot G; Goyard S; Guigon G; Milon G; Lang T
    PLoS Negl Trop Dis; 2007 Nov; 1(2):e34. PubMed ID: 18060082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity.
    Lecoeur H; Buffet PA; Milon G; Lang T
    Antimicrob Agents Chemother; 2010 Mar; 54(3):984-90. PubMed ID: 20038619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study.
    Soto JM; Toledo JT; Gutierrez P; Arboleda M; Nicholls RS; Padilla JR; Berman JD; English CK; Grogl M
    Am J Trop Med Hyg; 2002 Feb; 66(2):147-51. PubMed ID: 12135285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
    Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
    J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.
    Ben Salah A; Buffet PA; Morizot G; Ben Massoud N; Zâatour A; Ben Alaya N; Haj Hamida NB; El Ahmadi Z; Downs MT; Smith PL; Dellagi K; Grögl M
    PLoS Negl Trop Dis; 2009; 3(5):e432. PubMed ID: 19415122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation.
    Schwartz J; Moreno E; Fernández C; Navarro-Blasco I; Nguewa PA; Palop JA; Irache JM; Sanmartín C; Espuelas S
    Eur J Pharm Sci; 2014 Oct; 62():309-16. PubMed ID: 24964292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmanicidal potentials of
    Sharifi F; Sharififar F; Pournamdari M; Ansari M; Tavakoli Oliaee R; Bamorovat M; Khosravi A; Keyhani AR; Salarkia E; Mortazaeizdeh A; Dabiri S; Khamesipour A; Sharifi I
    J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34115583
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
    Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Bioluminescent Monitoring of Parasites in BALB/c Mouse Models of Cutaneous Leishmaniasis Drug Discovery.
    Caridha D; Leed S; Cawlfield A
    Methods Mol Biol; 2020; 2081():81-106. PubMed ID: 31721120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
    Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
    J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
    Schmidt-Ott R; Klenner T; Overath P; Aebischer T
    Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered
    Caridha D; Parriot S; Hudson TH; Lang T; Ngundam F; Leed S; Sena J; Harris M; O'Neil M; Sciotti R; Read L; Lecoeur H; Hickman M; Grogl M
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
    Eissa MM; Amer EI; El Sawy SM
    Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
    Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
    Bemani E; Oryan A; Bahrami S
    Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical paromomycin for New World cutaneous leishmaniasis.
    Sosa N; Pascale JM; Jiménez AI; Norwood JA; Kreishman-Detrick M; Weina PJ; Lawrence K; McCarthy WF; Adams RC; Scott C; Ransom J; Tang D; Grogl M
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007253. PubMed ID: 31048871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
    Bahrami S; Esmaeilzadeh S; Zarei M; Ahmadi F
    Parasitol Res; 2015 Dec; 114(12):4617-24. PubMed ID: 26346452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.